Structural & Congenital Heart Disease: TAVR outcomes | Ticagrelor & clopidogrel | Valve durability | ACC recommendations

The new study focused on the early outcomes of more than 24,000 patients who participated in a total of nine different studies.

The authors tracked data from more than 62,000 adult patients who received treatment from November 2011 to March 2019.

However, the two treatment options were associated with similar rates of long-term bleeding and ischemic events. 

The Sapien 3 prosthesis continues to impress, though researchers must continue to monitor its performance as time goes on.

“The association between surgeon experience and operative outcomes has been the subject of debate," the researchers explained.

The meta-analysis, published in the American Journal of Cardiology, explored data from six different randomized trials. 

The new guidance was designed to help clinicians provide high-quality care before, during and after TAVR procedures. 

More research on long-term outcomes is still needed before TAVR can be recommended for such patients across the board.